Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Jean Jacques Bienaime acquired 7,000 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were purchased at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now directly owns 23,615 shares in the company, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
Immunome Price Performance
NASDAQ IMNM opened at $6.95 on Wednesday. Immunome, Inc. has a 1-year low of $6.94 and a 1-year high of $26.70. The business has a 50 day simple moving average of $9.67 and a two-hundred day simple moving average of $11.44. The stock has a market capitalization of $604.31 million, a PE ratio of -0.86 and a beta of 1.93.
Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to analysts' expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on IMNM shares. Wedbush reiterated an "outperform" rating and issued a $33.00 price target on shares of Immunome in a research note on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They set an "outperform" rating and a $20.00 target price on the stock. Stephens restated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Finally, Guggenheim reduced their price objective on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $25.50.
Check Out Our Latest Stock Report on Immunome
Institutional Trading of Immunome
A number of large investors have recently made changes to their positions in IMNM. Enavate Sciences GP LLC purchased a new position in Immunome in the fourth quarter worth about $36,939,000. JPMorgan Chase & Co. boosted its holdings in shares of Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after purchasing an additional 624,045 shares during the period. Janus Henderson Group PLC increased its position in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock valued at $50,971,000 after purchasing an additional 324,614 shares during the last quarter. Granahan Investment Management LLC purchased a new stake in Immunome during the 4th quarter valued at $3,337,000. Finally, Renaissance Technologies LLC lifted its position in Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock worth $3,356,000 after buying an additional 304,700 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
